Fulgent to Participate in Upcoming Conferences

Core Insights - Fulgent Genetics, Inc. is scheduled to present at multiple upcoming investor conferences, including the UBS Global Healthcare Conference on November 10 and the Piper Sandler 37th Annual Healthcare Conference on December 2 [4] Company Overview - Fulgent is a technology-based company with a well-established laboratory services business and a therapeutic development business [2] - The laboratory services business includes technical laboratory services and professional interpretation of laboratory results by licensed physicians [2] - The therapeutic development business focuses on developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform [2] - The company aims to transition from a genomic diagnostic business to a fully integrated precision medicine company [2] Financial Performance - For the third quarter of 2025, Fulgent reported revenue of $84.1 million, representing a 17% year-over-year growth [6] - The company experienced a GAAP loss of $6.6 million, or $0.21 per share, while reporting a non-GAAP income of $4.5 million, or $0.14 per share [6]